Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK2 | P49760 | 3/20 | 0.76 |
| ▸ | CLK3 | P49761 | 3/20 | 0.76 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.76 |
| ▸ | AKT1 | P31749 | 13/20 | 0.52 |
| ▸ | PRKACA | P17612 | 6/20 | 0.52 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.52 |
| ▸ | PRKACG | P22612 | 5/20 | 0.52 |
| ▸ | PRKACB | P22694 | 5/20 | 0.52 |
| ▸ | CDK2 | P24941 | 4/20 | 0.52 |
| ▸ | PIM3 | Q86V86 | 4/20 | 0.52 |
| ▸ | CDK7 | P50613 | 3/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.52 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.52 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.52 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | PAK4 | O96013 | 2/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.52 |
| ▸ | PRKCG | P05129 | 2/20 | 0.52 |
| ▸ | PIM1 | P11309 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6855147 | 0.89 | CLK2 (0.61) | CLK2CLK3DYRK1AAKT1PRKACA | |
| SCHEMBL24317982 | 0.88 | CLK2 (0.69) | CLK2CLK3DYRK1AAKT1PRKACA | |
| SCHEMBL6926793 | 0.86 | AKT1 (0.62) | CLK2CLK3DYRK1AAKT1PRKACA | |
| SCHEMBL6857762 | 0.86 | AKT1 (0.62) | CLK2CLK3DYRK1AAKT1PRKACA | |
| SCHEMBL29367228 | 0.82 | AKT1 (0.75) | CLK2CLK3DYRK1AAKT1PRKACA | |
| SCHEMBL29386101 | 0.82 | AKT1 (0.75) | CLK2CLK3DYRK1AAKT1PRKACA | |
| SCHEMBL2191613 | 0.82 | AKT1 (0.75) | CLK2CLK3DYRK1AAKT1PRKACA | |
| SCHEMBL6857775 | 0.82 | AKT1 (0.75) | CLK2CLK3DYRK1AAKT1PRKACA | |
| SCHEMBL29388655 | 0.82 | AKT1 (0.75) | CLK2CLK3DYRK1AAKT1PRKACA | |
| SCHEMBL2191602 | 0.82 | AKT1 (0.75) | CLK2CLK3DYRK1AAKT1PRKACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000842-A1 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | VICKERS-SPLICE CO-INVESTMENT LLC (KY) | 2023-01-05 | — | — | US | disclosed |
| US-20220062240-A1 | METHODS OF TREATING CANCER USING A CLK INHIBITOR | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2022-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220062240-A1 | METHODS OF TREATING CANCER USING A CLK INHIBITOR | CLK2, CLK1, CLK3 | CLK2 1/4885CLK3 3/4885DYRK1A 1172/4885 |
| US-20230000842-A1 | METHODS OF TREATING CARTILAGE DISORDERS THROUGH INHIBITION OF CLK AND DYRK | CLK2, CLK3, CLK1 | CLK2 1/4885CLK3 2/4885DYRK1A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.